Journal of Pharmaceutical Analysis studies find promising drug candidates

Understanding the underlying mechanisms of normal and pathological cellular processes is an essential during the process of drug discovery for identifying new therapeutic drug candidates. Fortunately, modern analytical techniques, coupled with well-established in vitro and in vivo experimental methodologies, has greatly accelerated progress on this front. The latest issue of JPA features three articles in which candidate compounds for treating complex disorders were successfully identified, alongside their detailed mechanisms of action.

The first study investigated the use of metformin (Met), a drug used to manage type II diabetes, for treating benign prostate hyperplasia (BPH). The article was published in Volume 14, Issue 1 of the journal in January 2024. The researchers first sought to shed light on how and which dysregulated sex steroid hormone-related pathways shape the pathological characteristics of BPH, and whether Met can restore these pathways.

Through retrospective analysis of data from BPH patients and clinical assessment of serum and tissue samples, the researchers identified dihydrotestosterone (DHT) as a major contributor to BPH among dysregulated sex hormones. They found that DHT increased prostatic epithelial cell proliferation via the upregulation of androgen receptors and the subsequent formation of YAP1–TEAD4 heterodimers. Interestingly, in vivo experiments revealed that treatment with Met restored normal sex hormone homeostasis and exerted antiproliferative effects on DHT-affected cells. “Our study provided strong evidence that Met might be a promising clinical therapeutic approach for the treatment of BPH,” remark corresponding authors Prof. Qian Lu and Prof. Xiaoxing Yin.

In the second study, scientists explored the role of epimedin B (EB), the main flavonoid in the Chinese herb Epimedium brevicornum Maxim. in melanogenesis. This work builds upon prior research where researchers found that EB strongly induced melanogenesis and activated the tyrosinase family of proteins (TYRs). This time, through comprehensive experiments on human and animal cells in vitro and various animal models in vivo, they shed light on the molecular mechanisms by which EB modulated the activity, expression, and stability of TYRs. They found that EB increased the number of melanosomes and promoted their maturation, ameliorating depigmentation and bolstering repigmentation. “Our data reveals that EB can stimulate the pigmentation function of TYRs, which might provide a novel rational strategy for hypopigmentation treatment in the pharmaceutical and cosmetic industries,” comments corresponding authors Dr. Yiming Li and Prof. Huali Wu.

Finally, in the third study, researchers investigated the molecular mechanisms of ferroptosis, a type of programmed cell death, and how it related to nerve regeneration after peripheral nerve injury (PNI). First, they found that oxidative stress at the injury site not only triggered apoptosis in surrounding neurons, but also induced ferroptosis in neighbouring neurons. This occurred through an increase in intracellular iron, which in turn, happened through the degradation of iron export protein ferroportin driven by the protein UBA52. Using the Drug Signatures Database (DSigDB), the researchers then identified hydralazine (HYD), a potent arterial vasodilator, as a potential candidate to disrupt UBA52. In vivo experiments demonstrated that early administration of HYD after PNI led to faster axon regeneration and recovery of motor function, partially through the suppression of ferroptosis. “The potential clinical implementation of HYD may lead to a reduction in the prevalence of individuals with mild symptoms of nerve damage, consequently mitigating the societal burden,” conclude corresponding authors Dr. Bing Xia, Prof. Zhuojing Luo, and Dr. Jinghui Huang, excited about their findings.

Going ahead, it is expected that further studies will hopefully cement our understanding of the complex interplay between cellular processes, disease states, and drug candidates, ultimately leading us to new targeted and effective therapies.

***

Reference

Authors:

1. Tingting Yang^a, Jiayu Yuan^a, Yuting Peng^a, Jiale Pang^a, Zhen Qiu^a, Shangxiu Chen^a,b, Yuhan Huang^a,c, Zhenzhou Jiang^d, Yilin Fan^e, Junjie Liu^f, Tao Wang^c, Xueyan Zhou^a, Sitong Qian^a, Jinfang Song^a,g, Yi Xu^b, Qian Lu^a, Xiaoxing Yin^a
2. Chen Hong^h, Yifan Zhang^h, Lili Yangⁱ, Haoyang Xu^j, Kang Cheng^k, Zhi Lv^k, Kaixian Chen^h, Yiming Li^h, Huali Wu^h
3. Shengyou Li^L, Xue Gao^L, Yi Zheng^L, Yujie Yang^L, Jianbo Gao^L, Dan Geng^L, Lingli Guo^L, Teng Ma^L, Yiming Hao^L, Bin Wei^L, Liangliang Huang^L, Yitao Wei^L, Bing Xia^L, Zhuojing Luo^L, Jinghui Huang^L

Affiliations:

^aJiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University

^bDepartment of Pharmacy, Affiliated Lianyungang Hospital of Xuzhou Medical University

^cDepartment of Pharmacy, The Affiliated Hospital of Xuzhou Medical University

^dNew Drug Screening Center, Jiangsu Center for Pharmacodynamics Research and Evaluation, China Pharmaceutical University

^eSchool of Life Sciences, University of Essex

^fDepartment of Urology, The Affiliated Hospital of Xuzhou Medical University

^gDepartment of Pharmacy, Affiliated Hospital of Jiangnan University

^hDepartment of TCM Chemistry, School of Pharmacy, Shanghai University of Traditional Chinese Medicine

ⁱDepartment of Dermatology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

^jInternational Education College, Shanghai University of Traditional Chinese Medicine

^kShanghai Inoherb Cosmetics Co., Ltd., Shanghai

^LDepartment of Orthopedics, Xijing Hospital, Fourth Military Medical University

DOI:

1. https://doi.org/10.1016/j.jpha.2023.08.012
2. https://doi.org/10.1016/j.jpha.2023.09.006
3. https://doi.org/10.1016/j.jpha.2023.08.006